Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cyclo Therapeutics Inc
(NQ:
CYTH
)
0.6400
-0.0201 (-3.04%)
Streaming Delayed Price
Updated: 3:52 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cyclo Therapeutics Inc
< Previous
1
2
3
4
Next >
Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event
May 09, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event
March 29, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline
March 24, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 23, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results
March 14, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022
February 08, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
February 03, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
January 12, 2022
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /...
From
JTC Team, LLC
Via
AccessWire
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
December 09, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
December 06, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock
November 16, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Proposed Public Offering of Common Stock
November 16, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
November 16, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
November 10, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
November 04, 2021
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating...
From
JTC Team, LLC
Via
AccessWire
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
November 02, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
October 19, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
October 18, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
October 06, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
September 27, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
August 17, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
July 30, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
July 27, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
June 21, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
June 17, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Launch of New Website
June 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.